X-Therma's technology, a nontoxic biopreservation platform enabled by biomimetic peptoid, is transforming global accessibility to organ transplantation, as well as enabling 'off-the-shelf' cell and gene therapy products and engineered tissues by providing safe & effective chemically defined cryopreservation that is DMSO-, serum-, and protein-free.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/22/21 | $13,000,000 | Series A |
2b AHEAD Ventures Catalytic Impact Foundation Graphene Ventures LOREA AG  Methuselah Foundation VU Venture Partners Zen11 Holdings | undisclosed |
| 03/14/24 | $22,400,000 | Series B |
LOREA AG Starling Locke Capital | undisclosed |
